MCL1 and lymphoma: Using whole genome CRISPR/Cas9 KO screens, we identified loss of BAX as the top factor conferring resistance of both Trp53 wildtype and Trp53-deficient mouse Eμ-Myc lymphoma cell lines to BH3-mimetics targeting MCL-1.